Literature DB >> 14516206

DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.

Olga Novakova1, Haimei Chen, Oldrich Vrana, Alison Rodger, Peter J Sadler, Viktor Brabec.   

Abstract

Modifications of natural DNA in a cell-free medium by antitumor monodentate Ru(II) arene compounds of the general formula [(eta(6)-arene)Ru(en)Cl](+) (arene = biphenyl, dihydroanthracene, tetrahydroanthracene, p-cymene, or benzene; en = ethylenediamine) were studied by atomic absorption, melting behavior, transcription mapping, circular and linear dichroism, plasmid unwinding, competitive ethidium displacement, and differential pulse polarography. The results indicate that these complexes bind preferentially to guanine residues in double-helical DNA. The data are consistent with DNA binding of the complexes containing biphenyl, dihydroanthracene, or tetrahydroanthracene ligands that involves combined coordination to G N7 and noncovalent, hydrophobic interactions between the arene ligand and DNA, which may include arene intercalation and minor groove binding. In contrast, the single hydrocarbon rings in the p-cymene and benzene ruthenium complexes cannot interact with double-helical DNA by intercalation. Interestingly, the adducts of the complex containing p-cymene ligand, which has methyl and isopropyl substituents, distort the conformation and thermally destabilize double-helical DNA distinctly more than the adducts of the three multiring ruthenium arene compounds. It has been suggested that the different character of conformational alterations induced in DNA, and the resulting thermal destabilization, may affect differently further "downstream" effects of damaged DNA and consequently may result in different biological effects of this new class of metal-based antitumor compounds. The results point to a unique profile of DNA binding for Ru(II) arene compounds, suggesting that a search for new anticancer compounds based on this class of complexes may also lead to an altered profile of biological activity in comparison with that of metal-based antitumor drugs already used in the clinic or currently on clinical trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516206     DOI: 10.1021/bi034933u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  44 in total

1.  Synthesis, characterization, and reaction pathways for the formation of a GMP adduct of a cytotoxic thiocyanato ruthenium arene complex.

Authors:  Fuyi Wang; Abraha Habtemariam; Erwin P L van der Geer; Robert J Deeth; Robert Gould; Simon Parsons; Peter J Sadler
Journal:  J Biol Inorg Chem       Date:  2009-06-05       Impact factor: 3.358

2.  Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand.

Authors:  Raj K Koiri; Surendra K Trigun; Lallan Mishra; Kiran Pandey; Deobrat Dixit; Santosh K Dubey
Journal:  Invest New Drugs       Date:  2008-11-29       Impact factor: 3.850

3.  Reaction of the Anticancer Organometallic Ruthenium Compound, [(eta-p-Cymene)Ru(ATSC)Cl]PF(6) with Human Serum Albumin.

Authors:  Floyd A Beckford
Journal:  Int J Inorg Chem       Date:  2010-01-01

4.  Synthesis and structure of [(η(6)-p-cymene)Ru(2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide)Cl]Cl; biological evaluation, topoisomerase II inhibition and reaction with DNA and human serum albumin.

Authors:  Floyd Beckford; Jeffrey Thessing; Jason Woods; Jacob Didion; Nikolay Gerasimchuk; Antonio Gonzalez-Sarrias; Navindra P Seeram
Journal:  Metallomics       Date:  2011-02-23       Impact factor: 4.526

5.  Synthesis, characterization, DFT study, DNA/BSA-binding affinity, and cytotoxicity of some dinuclear and trinuclear gold(III) complexes.

Authors:  Snežana Radisavljević; Dušan Ćoćić; Snežana Jovanović; Biljana Šmit; Marijana Petković; Nevena Milivojević; Nevena Planojević; Snežana Marković; Biljana Petrović
Journal:  J Biol Inorg Chem       Date:  2019-09-05       Impact factor: 3.358

6.  Isomer separation and gas-phase configurations of organoruthenium anticancer complexes: ion mobility mass spectrometry and modeling.

Authors:  Jonathan P Williams; Tijana Bugarcic; Abraha Habtemariam; Kevin Giles; Iain Campuzano; P Mark Rodger; Peter J Sadler
Journal:  J Am Soc Mass Spectrom       Date:  2009-02-14       Impact factor: 3.109

Review 7.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

8.  Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes.

Authors:  Zuzana Sochorová Vokáčová; Iztok Turel; Jaroslav V Burda
Journal:  J Mol Model       Date:  2018-03-20       Impact factor: 1.810

9.  Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers.

Authors:  Haimei Chen; John A Parkinson; Olga Nováková; Juraj Bella; Fuyi Wang; Alice Dawson; Robert Gould; Simon Parsons; Viktor Brabec; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

10.  Biophysical studies on the stability of DNA intrastrand cross-links of transplatin.

Authors:  Jana Kasparkova; Victoria Marini; Vendula Bursova; Viktor Brabec
Journal:  Biophys J       Date:  2008-08-01       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.